EAM
AGIO icon

Erste Asset Management’s Agios Pharmaceuticals AGIO Stock Holding History

Erste Asset Management’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$82M Sell
2,154,900
-550,000
-20% -$16.7M 0.64% 30
2026
Q1 		$80.1M Sell
2,704,900
-100,000
-4% -$2.84M 0.74% 30
2025
Q4 		$76.3M Buy
2,804,900
+40,000
+1% +$1.4M 0.64% 36
2025
Q3 		$109M Buy
2,764,900
+438,411
+19% +$16.5M 1.05% 18
2025
Q2 		$77.4M Buy
2,326,489
+96,589
+4% +$2.93M 0.65% 31
2025
Q1 		$65.4M Buy
2,229,900
+220,000
+11% +$7.3M 0.84% 30
2024
Q4 		$66.4M Sell
2,009,900
-175,000
-8% -$8.22M 0.81% 28
2024
Q3 		$97.2M Sell
2,184,900
-70,000
-3% -$3.18M 1.16% 12
2024
Q2 		$97.3M Sell
2,254,900
-25,000
-1% -$902K 1.29% 11
2024
Q1 		$66.7M Buy
2,279,900
+172,000
+8% +$4.61M 0.91% 23
2023
Q4 		$47M Buy
2,107,900
+413,700
+24% +$9.27M 0.69% 41
2023
Q3 		$41.9M Hold
1,694,200
– – 0.72% 37
2023
Q2 		$47.9M Hold
1,694,200
– – 0.85% 26
2023
Q1 		$38.9M Hold
1,694,200
– – 0.74% 38
2022
Q4 		$47.5M Hold
1,694,200
– – 1% 18
2022
Q3 		$47.9M Sell
1,694,200
-35,000
-2% -$939K 1.07% 14
2022
Q2 		$38.3M Buy
1,729,200
+100,000
+6% +$2.26M 0.85% 29
2022
Q1 		$47.4M Buy
1,629,200
+51,000
+3% +$1.56M 0.91% 24
2021
Q4 		$53M Buy
1,578,200
+435,000
+38% +$17.5M 0.95% 19
2021
Q3 		$52.8M Buy
1,143,200
+59,300
+5% +$2.86M 1.04% 13
2021
Q2 		$59.6M Buy
1,083,900
+30,000
+3% +$1.68M 1.19% 12
2021
Q1 		$54.3M Hold
1,053,900
– – 1.33% 9
2020
Q4 		$46.9M Buy
1,053,900
+66,400
+7% +$2.63M 1.3% 10
2020
Q3 		$34.5M Buy
987,500
+77,400
+9% +$3.39M 1.18% 13
2020
Q2 		$48.6M Sell
910,100
-125,300
-12% -$5.8M 1.94% 4
2020
Q1 		$36.7M Sell
1,035,400
-43,300
-4% -$2M 2.14% 3
2019
Q4 		$51.8M Buy
1,078,700
+268,000
+33% +$10.1M 2.29% 5
2019
Q3 		$26.4M Buy
810,700
+116,000
+17% +$4.8M 1.41% 17
2019
Q2 		$34.6M Buy
694,700
+120,000
+21% +$6.41M 1.84% 7
2019
Q1 		$38.6M Buy
574,700
+15,100
+3% +$880K 2.16% 5
2018
Q4 		$25.3M Buy
+559,600
New +$34.5M 1.7% 10

Other funds holding AGIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Erste Asset Management's AGIO Position: Q2 2026 in Review

Erste Asset Management reduced its Agios Pharmaceuticals (AGIO) stake by 20% in Q2 2026, selling an estimated $16.7M and leaving 2,154,900 shares worth $82M. The position accounts for 0.64% of the portfolio, ranked #30.

Erste Asset Management first reported a position in AGIO in Q4 2018 and has held it in 31 quarters since. The position peaked at $109M in Q3 2025. 238 funds tracked by Wall St. Rank hold AGIO as of Q2 2026.

  • Erste Asset Management held 2,154,900 shares of Agios Pharmaceuticals worth $82M as of Q2 2026.
  • Erste Asset Management sold 550,000 Agios Pharmaceuticals shares in Q2 2026, an estimated $16.7M.
  • Agios Pharmaceuticals made up 0.64% of Erste Asset Management's portfolio in Q2 2026, its #30 holding.
  • Erste Asset Management first reported a position in Agios Pharmaceuticals in Q4 2018 and has held it in 31 quarters since.
  • Erste Asset Management's Agios Pharmaceuticals position peaked at $109M in Q3 2025.
  • 238 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q2 2026.

Based on Erste Asset Management's 13F filing for Q2 2026, filed 28 Jul 2026.